Therapeutic drug monitoring for immunosuppressants

Clinica Chimica Acta

Volumn 313, Issue 1-2, 2001, Pages 241-253

  Wong, Steven H Y ^a,b  

^a DYNACARE LABORATORIES   (Canada)

^b Milwaukee County Medical Examiner's Office   (United States)

Author keywords

Cyclosporine; Drug monitoring; Immunoassays; Immunosuppressants; Mycophenolic acid mofetil; Rapamycin; Tacrolimus

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

AREA UNDER THE CURVE; BIOPSY; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION FUNCTION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MONITORING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HEALTH SURVEY; HUMAN; HUMAN TISSUE; INFECTION; KIDNEY GRAFT; LIQUID CHROMATOGRAPHY; LIVER TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METHODOLOGY; MICROPARTICLE ENZYME IMMUNOASSAY; PATIENT COMPLIANCE; PRIORITY JOURNAL;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG MONITORING; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 0034751045     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(01)00678-7     Document Type: Conference Paper

References (93)

1. FK 506 - How much potential?
2. Immunosuppression in liver transplantation
3. Pharmacoeconomics of therapeutic drug monitoring in transplantation
4. Proceedings of the International Consensus Conference on Immunosuppressive Drugs
5. Toxic effects of immunosuppressive drugs: Mechanisms an strategies for controlling them
6. Proceedings of the 4th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology
7. 6th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology
8. Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring
9. Recommendations for bioequivalence testing of cylosporine generics revisited
10. Cyclosporine plasma unbound fraction in heart and lung transplantation recipients
11. Discovery of FK 506, a novel immunosuppressant isolated from Streptomyces tsukabaensis
12. FK 506, a novel immunosuppressant isolated from a Streptomyces: I. Fermentation, isolation, and physico-chemical and biological characteristics
13. FK 506, a novel immunosuppressant isolated from a Streptomyces: II. Immunosupressive effect of FK 506 in vitro
14. A receptor for the immunosuppressant FK 506 is a cis-trans peptidyl-prolyl isomerase
15. A cytosolic binding protein for the immunosuppressant FK 506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin
16. FK 506 for liver, kidney, and pancreas transplantation
17. FK 506: Historical perspectives
18. FK 506 (Tacrolimus), a novel immunosuppressant in organ transplantation: Clinical, biomedical, and analytical aspects
19. A comparison of Tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation
20. Randomized trial comparing tacrolimus (FK 506) and cyclosporin in prevention of liver allograft rejection
21. Clinical pharmacokinetics of tacrolimus in heart transplant recipients
22. High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients
23. Specific and sensitive measurement of FK 506 and its metabolites in blood and urine of liver-graft recipients
24. Tacrolimus (FK 506) metabolite patterns in blood from liver and kidney transplant patients
25. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation
26. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolic mofetil
27. Assessment of mycophenolic acid-induced immunosuppression; A new approach
28. The apparent inhibition of inosine monophosphate dehydrogenase by mycophenolic acid glucuronide is attributable to the presence of trace quantities of mycophenolic acid
29. Determination of the newly detected pharmacologically active acyl glucuronide metabolite of mycophenolic acid by HPLC
30. Determination of the acyl glucuronide metabolite of mycopenolic acid in human plasma by HPLC and EMIT
31. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation
32. Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid
33. Mycophenolic acid plasma concentrations: Influence of comedication
34. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid
35. Pharmacokinetics of mycophenolic acid in renal insufficiency
36. Area under the plasma concentration-time curve for total, but not free, mycophenolic acid increases in the stable phase after renal transplantation: A longitudinal study in pediatric patients
37. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring
38. Introduction and overview - Advances in therapeutic drug monitoring for immunosuppressants: A review of sirolimus
39. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus
40. Pharmacokinetics and metabolism of sirolimus
41. Pharmacokinetics and safety of single oral doses of sirolimus (Rapamycin) in healthy male volunteers
42. Correlation between pretransplantation test dose cyclosporine pharmacokinetic profiles and posttransplantation sirolimus blood levels in renal transplant recipients
43. Consensus document therapeutic monitoring of tacrolimus, (FK 506)
44. Plasma vs. whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression
45. Limited sampling strategy for the determination of mycophenolic acid AUC in pediatric kidney recipients
46. Therapeutic monitoring of mycophenolic acid: A consensus panel report
47. Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation
48. Toxicity and efficacy of sirolimus: Relationship to whole-blood concentrations
49. Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de Novo renal transplant patients treated with Sandimmune or Neoral
50. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients
51. Failure of traditional trough levels to predict tacrolimus concentrations
52. A randomized, double-blind, plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation
53. Stability of mycophenolic acid and mycophenolic glucuronide in human plasma
54. An immunophilin-binding assay for sirolimus
55. Radioreceptor assay for quantifying FK-506 immunosuppressant in whole blood
56. Immunophilins: Their properties and their potential role in therapeutic drug monitoring
57. Pentamer formation assay based on drug functional mechanisms
58. New approached to cyclosporine monitoring raise further concerns about analytical techniques
59. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: How specific is specific?
60. Evaluation of the AxSYM monoclonal cyclosporin assay and comparison with radioimmunoassay
61. Evaluation of the new AxSYM cyclosporine assay; Comparison with TDx monoclonal whole blood and Emit cyclosporine assay
62. Cyclosporin assays, metabolite cross-reactivity, and pharmacokinetic monitoring
63. A whole blood FK 506 assay for the IMx analyzer
64. Clinical efficacy of the Abbott Tacrolimus II Assay for the IMx
65. Comparison of tacrolimus concentrations measured by the IMx Tacrolimus II vs. the Pro-Trac II FK 506 ELISA assays
66. Therapeutic monitoring of tacrolimus (FK 506) with the first and second generation microparticle enzyme immunoassays: Performance and results in four patient populations
67. Performance of the IMx Tacrolimus II assay and practical limits of detection
68. Sensitive, specific quantitative analysis of tacrolimus (FK 506) in blood by liquid chromatography-electrospray tandem mass spectrometry
69. Analysis of whole blood tacrolimus concentrations in liver transplant patients exhibiting impaired liver function
70. Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid
71. Analytical performance of an EMIT assay for mycophenolic acid in plasma
72. Pharmacodynamic assessment of pycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity
73. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients
74. Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry
75. A practical guide to the analysis of sirolimus using high-performance liquid chromatography with ultraviolet detection
76. Therapeutic monitoring of sirolimus in human whole-blood samples by high-performance liquid chromatography
77. Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection
78. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection
79. Analytical performance of microparticle enzyme immunoassay and HPLC-Tandem mass spectrometry in the determination of sirolimus in whole blood
80. The quantification of sirolimus by high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in renal transplant recipients
81. An immunoassay for the measurement of sirolimus
82. An immunoassay for the measurement of sirolimus
83. Accuracy of cyclosporin measurements made in capillary blood samples obtained by skin puncture
84. Stability of sirolimus (Rapamycin) in whole blood
85. Proficiency-testing issues relating to sirolimus
86. Prediction of tacrolimus blood levels by using the neural network with genetic algorithm in liver transplantation patients
87. The FTY720 story
88. A specific artificial antibody toward mycophenolic acid prepared by molecular imprinting
89. Cytokines and their receptors: An overview
90. A case report of postmortem immunosuppressant concentrations